Reporting from ECCMID17, we spoke to William Irving about his current work on hepatitis C and his thoughts on the future of this field.
Browsing: Viral > Hepatitis
In this clinical trial focus, the authors discuss difficult-to-treat patients with autoimmune hepatitis, and the potential of additional treatment option JKB-122.
Genotyping hepatitis C patients with advanced cirrhosis could help predict improvement after treatment, according to research presented at Digestive Disease Week®.
In this interview, Joop Arends discusses his thoughts on the future of diagnosis and management of hepatitis C, and also gives us his highlights from ECCMID.
In line with Hepatitis Awareness Month, we spoke to Marcus Dorner about his current research into the host–virus interactions in hepatitis B and C infection, their implications for vaccine development and more.
Researchers have demonstrated that both hepatitis B and hepatitis C infection are associated with an increased risk of Parkinson’s disease.
A new systematic evidence review has discovered that FDA-approved direct-acting antiviral regimens are effective against all genotypes of hepatitis C.
In this editorial the author examines the initiatives taken by Drugs for Neglected Diseases (DNDi) and Medicines Patent Pool (MPP) organizations to improve access to pan-genotypic hepatitis C treatment.